A Phase 1 interventional study of sildenafil citrate 100 mg CT and sildenafil citrate 100 mg CT in Erectile Dysfunction, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 1 site in Brazil. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing sildenafil in Erectile Dysfunction — 1 open to participants now, 1 under way, 1 of them phase 3. sildenafil · Erectile Dysfunction.
Among the 50 studies testing sildenafil in Erectile Dysfunction, this one is the 37th largest by enrollment, is one of 3 that started in 2010, is one of 6 in phase 1, and was the 31st registered.
702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.
Browse Erectile Dysfunction studies →1 of the 50 studies testing sildenafil in Erectile Dysfunction is open now. Recruiting first, the newest first:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 50 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 6 · Phase 4 30
First in 2002; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 47 is below the median of 70 across 551 interventional studies indexed under Erectile Dysfunction.
Median enrollment 108 across the 50 interventional studies. Of the 38 that completed or were terminated, 6 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
27 studies in Erectile Dysfunction by Viatris Inc.: none open now, none under way, none of them phase 3. Of 27 finished, 5 (19%) have results posted.
Among the 27 studies in Erectile Dysfunction by Viatris Inc., this one is the 20th largest by enrollment of the 24 interventional ones that give a count, is one of 5 that started in 2010, is one of 5 in phase 1, and was the 23rd registered.
Viatris Inc.’s Erectile Dysfunction studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing sildenafil in Erectile Dysfunction, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 27 in Erectile Dysfunction:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to perform a relative bioavailability study between two formulations of sildenafil citrate.
Bio-equivalence between two formulations of sildenafil citrate
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: sildenafil citrate 100 mg CT
Drug: sildenafil citrate 100 mg CT
Drug: Viagra®
sildenafil citrate 100 mg CT, single dose without water
sildenafil citrate 100 mg CT, single dose with water
sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
Area Under the Curve (AUC 0-t)
Area under the blood concentration-time profile from time zero to last experimentally determined concentration measured in nanograms\*hour/milliliter (ng\*hr/mL).
Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Maximum Plasma Concentration (Cmax)
Maximum plasma concentration measured in nanograms per milliliter (ng/mL).
Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Area Under the Curve From 0 to Infinity (AUC 0-inf )
Area under the blood concentration-time profile from time zero extrapolated to infinite time measured in nanograms \*hour/milliliter (ng\*hr/mL).
Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Time to Maximum Plasma Concentration (Tmax)
Time at which maximum plasma concentration (Cmax) occurred.
Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Half-life (T 1/2)
Terminal elimination half-life.
Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, and 12 hours post-dose
Number of Participants With Clinically Significant Findings in Vital Signs
Clinically significant abnormalities in blood pressure (BP), pulse, and temperature reported as an adverse event. Clinically significant = values outside the normal range and/or values judged as significant by the investigator (normal range: systolic BP 100-140 mmHg; diastolic BP 60- 90 mmHg; temperature 35-37°Celsius). Pulse rate based on investigator discretion.
Time frame: Day 1 (Period 1), Day 8 (Period 2), and Day 15 (Period 3): Pre-dose and 0.5, 1, 2, 4, 8 and 12 hours post-dose.
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 | 8 |
| Received treatment | 8 | 8 | 8 | 8 | 7 | 8 |
| Completed | 7 | 7 | 7 | 6 | 7 | 8 |
| Not completed | 1 | 1 | 1 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 | 0 |
Area under the blood concentration-time profile from time zero to last experimentally determined concentration measured in nanograms\*hour/milliliter (ng\*hr/mL).
| ng*hr/mL | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water |
|---|---|---|---|
| Area Under the Curve (AUC 0-t) | 1467.00 ± 560.99 | 1458.45 ± 602.73 | 1493.53 ± 615.59 |
Maximum plasma concentration measured in nanograms per milliliter (ng/mL).
| ng/mL | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water |
|---|---|---|---|
| Maximum Plasma Concentration (Cmax) | 439.38 ± 198.25 | 434.38 ± 211.53 | 532.31 ± 217.32 |
Area under the blood concentration-time profile from time zero extrapolated to infinite time measured in nanograms \*hour/milliliter (ng\*hr/mL).
| ng*hr/mL | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water |
|---|---|---|---|
| Area Under the Curve From 0 to Infinity (AUC 0-inf ) | 1547.92 ± 588.48 | 1534.66 ± 618.86 | 1573.81 ± 648.32 |
Time at which maximum plasma concentration (Cmax) occurred.
| hours | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water |
|---|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) | 1.46 ± 0.81 | 1.29 ± 0.71 | 1.28 ± 0.85 |
Terminal elimination half-life.
| hours | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water |
|---|---|---|---|
| Half-life (T 1/2) | 2.96 ± 0.63 | 2.84 ± 0.74 | 2.93 ± 0.81 |
Clinically significant abnormalities in blood pressure (BP), pulse, and temperature reported as an adverse event. Clinically significant = values outside the normal range and/or values judged as significant by the investigator (normal range: systolic BP 100-140 mmHg; diastolic BP 60- 90 mmHg; temperature 35-37°Celsius). Pulse rate based on investigator discretion.
| participants | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water |
|---|---|---|---|
| Number of Participants With Clinically Significant Findings in Vital Signs | 0 | 1 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test 1: 100 mg Chewable, Without Water | — | 0/47 (0%) | 3/47 (6.4%) |
| Test 2: 100 mg Chewable, With Water | — | 0/47 (0%) | 3/47 (6.4%) |
| Reference: 100 mg Coated, With Water | — | 0/47 (0%) | 3/47 (6.4%) |
| Formulation Unspecified | — | 0/47 (0%) | 18/47 (38.3%) |
| Event | Test 1: 100 mg Chewable, Without Water | Test 2: 100 mg Chewable, With Water | Reference: 100 mg Coated, With Water | Formulation Unspecified |
|---|---|---|---|---|
| Laboratory change: urineGeneral disorders | 0/47 | 0/47 | 0/47 | 8/47 |
| Laboratory change: red blood cell countGeneral disorders | 0/47 | 0/47 | 0/47 | 4/47 |
| HeadacheGeneral disorders | 3/47 | 2/47 | 2/47 | 0/47 |
| Laboratory change: glucoseGeneral disorders | 0/47 | 0/47 | 0/47 | 3/47 |
| Laboratory change: triglyceridesGeneral disorders | 0/47 | 0/47 | 0/47 | 2/47 |
| Laboratory change: cholesterolGeneral disorders | 0/47 | 0/47 | 0/47 | 2/47 |
| Laboratory changes unspecifiedGeneral disorders | 0/47 | 0/47 | 0/47 | 2/47 |
| NauseaGeneral disorders | 1/47 | 0/47 | 1/47 | 0/47 |
| Loose stoolsGeneral disorders | 1/47 | 0/47 | 0/47 | 0/47 |
| HypotensionGeneral disorders | 0/47 | 1/47 | 0/47 | 0/47 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 29.3 (18 to 45) |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 0 |
| Male | 48 |
The record gives a start of Jan 2010, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →